{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Status:
Investigational
Source:
NCT01120600: Phase 3 Interventional Completed Osteoporosis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor, an enzyme involved in bone resorption. Merck & Co was developing odanacatib, a once-weekly, oral Odanacatib, for the treatment of postmenopausal osteoporosis and osteoporosis in men. Merck & Co. has discontinued development of its cathepsin K inhibitor odanacatib, citing an increased risk of cardiovascular events for the osteoporosis drug.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Eflucimibe is a new and potent Acyl coenzyme A:cholesterol acyltransferases inhibitor. Eflucimibe effectively decreased plasma cholesterol in cholesterol-fed animals. In animal models, drug restores normolipodemia in endogenous hypercholesterolemic rabbits and prevents the progression of atherosclerosis by decreasing the number of macrophages in the foam cells. Eflucimibe has been in phase II clinical trials for the treatment of atherosclerosis and hyperlipidemia. However, this research has been discontinued.
Status:
Investigational
Source:
NCT00959881: Phase 1 Interventional Completed Healthy Subjects
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Begacestat (GSI-953 or PF-5212362), a gamma-secretase inhibitor (GSI) that selectively inhibits cleavage of APP over Notch, was discovered for the treatment of Alzheimer's disease. The drug has shown promise results in phase I clinical trials, however further studies were discontinued.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulfachrysoidine is a sulfamylchrysoidine derivative and lipid-soluble azo dye with antibacterial activity.
Status:
Investigational
Source:
NCT00267254: Phase 3 Interventional Completed Hyperlipidemia
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Torcetrapib is a CETP inhibitor which was developed by Pfizer for the treatment of diseases associated with elevated level of cholesterol. The drug was tested in phase III (in combination with atorvastatin) of clinical trials in coronary heart disease patients as well as in patients with hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, however its development was terminated due to the high risk of death and heart problems.
Status:
Investigational
Source:
INN:norpipanone [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Norpipanone (Orfenso; Hexalgon) is an opioid analgesic. It is a controlled substance (opiate).
Status:
Investigational
Source:
NCT02226939: Phase 2 Interventional Completed Liver Cirrhosis
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Ciluprevir (BILN-2061) is a selective inhibitor of the HCV NS3 serine protease, which was developed by Boehringer Ingelheim for the treatment of hepatitis C infection. The drug was discontinued in phase II due to adverse events such as cardiac toxicity (demonstrated in animals). In the cell-based replicon assay, ciluprevir inhibited HCV RNA replication at low nanomolar levels. It had inhibitory rate constant (Ki) values of 0.3 and 0.66 nM for the NS3 proteases of HCV genotypes 1a and -1b, respectively.
Status:
Investigational
Source:
NCT00779480: Phase 1 Interventional Terminated Acute Myelogenous Leukemia (AML)
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukaemia patients. KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase with IC50 values of 6.6nM, 14nM, 4nM and 48nM, respectively. KW-2449 has potent growth inhibitory activity against various types of leukaemia by several mechanisms of action. Kyowa Hakko Kirin Pharma Inc. (a US subsidiary of Kyowa Hakko Kirin Co) was developing KW-2449 for the treatment of acute lymphoblastic leukaemia; acute myeloid leukaemia; chronic myeloid leukaemia; myelodysplastic syndromes, but later these studies were discontinued.
Class (Stereo):
CHEMICAL (MIXED)
Iodetryl is fatty acid derivative patented by Russian company OOO "Nauchno-Proizvodstvennaya Firma "I. M. A." as a colloidal contrast agent.
Status:
Investigational
Source:
NCT00282724: Phase 2/Phase 3 Interventional Completed Ichthyosis, Lamellar
(2006)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Liarozole is an imidazole-containing compound that inhibits the cytochrome P-450-dependent metabolism of all-trans-retinoic acid (RA). Liarozole, a retinoic acid (RA) metabolism-blocking agent
(RAMBA) in clinical development, has been granted orphan
drug designation for congenital ichthyosis by the European
Commission and the U.S. Food and Drug Administration. Later, based on the mixed results from a phase II/III trial of liarozole for the treatment of ichthyosis, Barrier decided to discontinue the development of liarozole. Liarozole displays antitumor activity against androgen-dependent and independent rat prostate carcinomas.A large phase III international study was completed
comparing liarozole 300 mg twice daily with cyproterone
acetate (CPA) 100 mg twice daily in a total of 321
patients with metastatic prostate cancer in relapse after
first-line endocrine therapy. The results
indicate that liarozole might be a possible treatment
option for prostate cancer (PCA) following failure of
first-line endocrine therapy.
